Date 03/12/2007

ARDANA PLC ANNOUNCES OUTCOME OF STRATEGIC REVIEW

Edinburgh, UK, November 26 2007: Ardana Plc (LSE:ARA), the pharmaceutical company focused on improving human reproductive health, today announces positive preliminary results from a differentiation study of its Testosterone Cream for the treatment of testosterone deficiency in men.

Date 26/11/2007

ARDANA ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM A DIFFERENTIATION STUDY OF ITS TESTOSTERONE CREAM IN MALE HYPOGONADISM

Edinburgh, UK, November 26 2007: Ardana Plc (LSE:ARA), the pharmaceutical company focused on improving human reproductive health, today announces positive preliminary results from a differentiation study of its Testosterone Cream for the treatment of testosterone deficiency in men.

Date 21/11/2007

ARDANA ANNOUNCES POSITIVE PRELIMINARY RESULTS IN A FURTHER PHASE II STUDY OF TEVERELIX LA IN BENIGN PROSTATIC HYPERPLASIA

Edinburgh, UK, 21 November 2007: Ardana plc (LSE:ARA) today announces positive preliminary results from a Phase II study of its key compound, the GnRH antagonist Teverelix Long Acting (LA), which shows that patients may only need to have two maintenance doses per year to treat the symptoms of benign prostatic hyperplasia (BPH), a significant potential improvement over current treatments.

Date 21/11/2007

Date 09/10/2007

ARDANA ANNOUNCES INTERIM RESULTS

Edinburgh, UK: 9 October 2007 : Ardana announces its Interim Results for the six months ended 30 September 2007

Date 08/10/2007

ARDANA ANNOUNCES BOARD CHANGE

Edinburgh, UK: 8 October 2007 : Ardana announces that the Company’s Chief Executive Officer, Dr. Maureen Lindsay, has informed the Board that, after nearly 7 years of service, she wishes to step down from her position as CEO and a Director of the Company

Date 24/09/2007

ARDANA INFORMATION UPDATE

Edinburgh, UK: 24 September 2007 : This annual information update is filed pursuant to Prospectus Rule 5.2 made by the Financial Services Authority and not for any other purpose

Date 05/09/2007

RESULTS OF RESOLUTIONS PASSED AT ANNUAL GENERAL MEETING

Edinburgh, UK: 5 September 2007 : Ardana plc announces the result of voting on the resolutions at its annual general meeting (“AGM”) held on Wednesday 5 September 2007.

Date 04/09/2007

ARDANA ANNOUNCES POSITIVE PRELIMINARY PHASE II RESULTS FOR TEVERELIX LA IN PROSTATE CANCER

Edinburgh, UK: 4 September 2007 :  Ardana plc (LSE:ARA) today announces positive preliminary results from a Phase II study in patients with prostate cancer demonstrating a new dose regimen extended to 8 weeks from 4 weeks for its lead development compound, the GnRH antagonist, Teverelix Long-Acting (LA). 

Date 10/08/2007

ARDANA : INTERIM MANAGEMENT STATEMENT - 3 MONTHS ENDED 30 JUNE 2007

Edinburgh, UK: 10 August 2007 :  Ardana plc (LSE:ARA) is today issuing its first Interim Management Statement (“IMS”).  This IMS has been produced solely to provide additional information to shareholders as a body to meet the relevant requirements of the UK Listing Authority’s Disclosure and Transparency Rules.  It should not be relied upon by any other party or for any other purpose.

Date 08/08/2007

ARDANA COMMENCES PHASE III REGISTRATION TRIAL FOR ITS ORAL GROWTH HORMONE SECRETAGOGUE DIAGNOSTIC

Edinburgh, UK: 8 August 2007 :  Ardana plc (LSE:ARA) today announces the commencement in the USA of a planned pivotal registration study of its oral growth hormone secretagogue (GHS) ARD-07 which is in development for the diagnosis of growth hormone deficiency in adults.  The first patient has now been enrolled in the study.

Date 28/06/2007

Ardana: Preliminary Announcement for the year ended 31 March 2007

Edinburgh, UK, 28 June 2007:  Ardana plc (LSE: ARA), the pharmaceutical company focused on the discovery, development and marketing of innovative products to improve human reproductive health, today announces its Preliminary Results for the year ended 31 March 2007.

Date 28/06/2007

ARDANA BOARD CHANGES

Edinburgh, UK, 28 June 2007:   Ardana, the company focused on improving human reproductive health, today announces the appointment of Dr Chris Moyses to its Board of Directors as a non-executive director and the retirement from the Board of Ian Kent after seven years’ service.  Both changes are with immediate effect.

Date 11/06/2007

ARDANA ANNOUNCES POSITIVE ASSESSMENT OF EMSELEX® BY SCOTTISH MEDICINES CONSORTIUM 

Edinburgh, UK, 11 June 2007:  Ardana plc (LSE:ARA), today announces a positive opinion from the Scottish Medicines Consortium (SMC) about Emselex (darifenacin hydrobromide). Emselex is a once a day oral treatment for the symptoms of overactive bladder (OAB). A positive opinion  by the SMC is essential for the introduction of new therapies within NHS Scotland

ARDANA'S ORAL GROWTH HORMONE SECRETAGOGUE GAINS ORPHAN DRUG STATUS

Edinburgh, UK, 21 May 2007;  Ardana plc (LSE:ARA) today announces that the US Food and Drug Administration (FDA) has granted Orphan Drug status for ARD-07, its oral Growth Hormone Secretagogue (GHS), which Ardana is developing as a diagnostic for growth hormone deficiency in adults.

ARDANA TO PRESENT AT COWEN & COMPANY ANNUAL HEALTH CARE CONFERENCE IN NEW YORK

http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=**ARA&item_id=1494107

ARDANA ANNOUNCES FAVOURABLE PRELIMINARY RESULTS FOR TEVERELIX LA IN DEVELOPMENT FOR PROSTATE CANCER

Edinburgh, UK, 14 February 2007 - Ardana plc (LSE:ARA) today announces preliminary results from a study in male subjects of its lead development compound, the GnRH antagonist Teverelix Long Acting (LA).

ARDANA SIGNS AGREEMENT WITH TWINPHARMA TO MARKET STRIANT™ SR IN THE NETHERLANDS

Edinburgh, UK, 13 February 2007:  Ardana plc (LSE:ARA) today announces that it has signed an agreement granting TwinPharma BV (“TwinPharma”) exclusive rights to market Striant™ SR in the Netherlands.